AVITA Medical (RCEL) Cash from Operations Growth (1y) (2020 - 2025)
AVITA Medical (RCEL) Cash from Operations Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 185.96% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 122.43% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 16.00% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | AVITA Medical | 140.94 Mn | 124.59 Mn | 14.31 Mn | 32.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.71% |
| Sep 30, 2025 | 27.65% |
| Jun 30, 2025 | 19.96% |
| Mar 31, 2025 | 50.59% |
| Dec 31, 2024 | 25.61% |
| Sep 30, 2024 | 19.61% |
| Jun 30, 2024 | -40.42% |
| Mar 31, 2024 | -129.96% |
| Dec 31, 2023 | -258.70% |
| Mar 31, 2023 | 3.17% |
| Mar 31, 2022 | -9.71% |
| Sep 30, 2021 | -70.22% |
| Mar 31, 2021 | -17.08% |
| Dec 31, 2020 | -21.96% |
| Sep 30, 2020 | -58.02% |